Contact
searchSearch
HMP Global
Login

Alzheimer & Dementia Related Cognitive Disorders Topic Center

person holding cannabis
Cannabis Use Requiring Acute Care Increases Dementia Risk
04/22/2025
Jolynn Tumolo
People aged 45 years or older with an acute care encounter due to cannabis use had a 3.9-fold higher risk of a new dementia diagnosis within 5 years compared with the general population, according to a recent study.
People aged 45 years or older with an acute care encounter due to cannabis use had a 3.9-fold higher risk of a new dementia diagnosis within 5 years compared with the general population, according to a recent study.
People aged 45 years or older...
04/22/2025
Neurology
From Neurology
Neurons in the brain
News
Risk Factors for Late-Onset Epilepsy in Patients With Cognitive Decline Identified
04/21/2025
Jolynn Tumolo
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk...
04/21/2025
Neurology
From Neurology
A doctor and patient talk
News
Later Life Depressive Symptoms Not Linked With Amyloid Accumulation
03/04/2025
Jolynn Tumolo
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal...
03/04/2025
Psych Congress Network
FDA building
News
FDA Approves Once-Monthly Lecanemab-irmb Dosing for Early Alzheimer Disease
01/28/2025
Meagan Thistle
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a...
01/28/2025
Psych Congress Network
US FDA sign
News
Posdinemab Granted Fast Track Designation by the FDA for Early Alzheimer Disease
01/10/2025
Brionna Mendoza
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated...
01/10/2025
Psych Congress Network
a researcher examines MRI scans
News
Diabetes, Amyloid Pathology Linked With Progression to MCI Over 20 Years
01/02/2025
Jolynn Tumolo
Type 2 diabetes and an abnormal amyloid-β concentration in cerebrospinal fluid were associated with accelerated brain atrophy and an earlier progression to mild cognitive impairment (MCI) in a cohort study.
Type 2 diabetes and an abnormal amyloid-β concentration in cerebrospinal fluid were associated with accelerated brain atrophy and an earlier progression to mild cognitive impairment (MCI) in a cohort study.
Type 2 diabetes and an abnormal...
01/02/2025
Neurology
From Neurology
Regular Physical Activity After Dementia Diagnosis May Lower Mortality Risk
News
Regular Physical Activity After Dementia Diagnosis May Lower Mortality Risk
11/21/2024
Evi Arthur
Regular physical activity (PA) following dementia diagnosis could lower the risk of all-cause mortality, according to results from a retrospective cohort study published in the British Journal of Sports Medicine.
Regular physical activity (PA) following dementia diagnosis could lower the risk of all-cause mortality, according to results from a retrospective cohort study published in the British Journal of Sports Medicine.
Regular physical activity (PA)...
11/21/2024
Psych Congress Network
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Jolynn Tumolo
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network
An elderly woman sits on a couch
News
Increasing Depression Symptoms in Older Adults Associated With Amyloid Accumulation
09/09/2024
Brionna Mendoza
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms...
09/09/2024
Psych Congress Network
an older adult lies in a hospital bed with head turned looking out of a window
News
Suvorexant Associated With Lower Delirium Rates in Some Hospitalized Older Adults
08/29/2024
Jolynn Tumolo
Suvorexant, a sleep-promoting orexin receptor antagonist, was associated with lower rates of delirium than placebo in hospitalized older adults at high risk of delirium, but the difference was not statistically significant.
Suvorexant, a sleep-promoting orexin receptor antagonist, was associated with lower rates of delirium than placebo in hospitalized older adults at high risk of delirium, but the difference was not statistically significant.
Suvorexant, a sleep-promoting...
08/29/2024
Psych Congress Network
Collaborative Dementia Care Tied with Improved Outcomes
News
Collaborative Dementia Care Tied With Improved Outcomes
08/14/2024
Evi Arthur
Collaborative dementia care management (CDCM) was associated with improved patient and caregiver outcomes over 3 years after the initial care period, according to results from a randomized controlled trial published in JAMA Network Open. U
Collaborative dementia care management (CDCM) was associated with improved patient and caregiver outcomes over 3 years after the initial care period, according to results from a randomized controlled trial published in JAMA Network Open. U
Collaborative dementia care...
08/14/2024
Neurology
From Neurology

News

Neurons in the brain
News
Risk Factors for Late-Onset Epilepsy in Patients With Cognitive Decline Identified
04/21/2025
Jolynn Tumolo
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk...
04/21/2025
Neurology
A doctor and patient talk
News
Later Life Depressive Symptoms Not Linked With Amyloid Accumulation
03/04/2025
Jolynn Tumolo
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal...
03/04/2025
Psych Congress Network
FDA building
News
FDA Approves Once-Monthly Lecanemab-irmb Dosing for Early Alzheimer Disease
01/28/2025
Meagan Thistle
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a...
01/28/2025
Psych Congress Network
US FDA sign
News
Posdinemab Granted Fast Track Designation by the FDA for Early Alzheimer Disease
01/10/2025
Brionna Mendoza
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated...
01/10/2025
Psych Congress Network
a researcher examines MRI scans
News
Diabetes, Amyloid Pathology Linked With Progression to MCI Over 20 Years
01/02/2025
Jolynn Tumolo
Type 2 diabetes and an abnormal amyloid-β concentration in cerebrospinal fluid were associated with accelerated brain atrophy and an earlier progression to mild cognitive impairment (MCI) in a cohort study.
Type 2 diabetes and an abnormal amyloid-β concentration in cerebrospinal fluid were associated with accelerated brain atrophy and an earlier progression to mild cognitive impairment (MCI) in a cohort study.
Type 2 diabetes and an abnormal...
01/02/2025
Neurology
Regular Physical Activity After Dementia Diagnosis May Lower Mortality Risk
News
Regular Physical Activity After Dementia Diagnosis May Lower Mortality Risk
11/21/2024
Evi Arthur
Regular physical activity (PA) following dementia diagnosis could lower the risk of all-cause mortality, according to results from a retrospective cohort study published in the British Journal of Sports Medicine.
Regular physical activity (PA) following dementia diagnosis could lower the risk of all-cause mortality, according to results from a retrospective cohort study published in the British Journal of Sports Medicine.
Regular physical activity (PA)...
11/21/2024
Psych Congress Network
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Jolynn Tumolo
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network
An elderly woman sits on a couch
News
Increasing Depression Symptoms in Older Adults Associated With Amyloid Accumulation
09/09/2024
Brionna Mendoza
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms in older adults were associated with early amyloid accumulation in regions responsible for emotional control, and may foretell later Alzheimer Disease (AD) development
Increasing depression symptoms...
09/09/2024
Psych Congress Network
an older adult lies in a hospital bed with head turned looking out of a window
News
Suvorexant Associated With Lower Delirium Rates in Some Hospitalized Older Adults
08/29/2024
Jolynn Tumolo
Suvorexant, a sleep-promoting orexin receptor antagonist, was associated with lower rates of delirium than placebo in hospitalized older adults at high risk of delirium, but the difference was not statistically significant.
Suvorexant, a sleep-promoting orexin receptor antagonist, was associated with lower rates of delirium than placebo in hospitalized older adults at high risk of delirium, but the difference was not statistically significant.
Suvorexant, a sleep-promoting...
08/29/2024
Psych Congress Network
Collaborative Dementia Care Tied with Improved Outcomes
News
Collaborative Dementia Care Tied With Improved Outcomes
08/14/2024
Evi Arthur
Collaborative dementia care management (CDCM) was associated with improved patient and caregiver outcomes over 3 years after the initial care period, according to results from a randomized controlled trial published in JAMA Network Open. U
Collaborative dementia care management (CDCM) was associated with improved patient and caregiver outcomes over 3 years after the initial care period, according to results from a randomized controlled trial published in JAMA Network Open. U
Collaborative dementia care...
08/14/2024
Neurology
open and spilled bottle of pills
News
Beta-Blockers Ineffective for Treating Psychological Symptoms of Anxiety
04/24/2025
Maria Mantas
A systematic review found no evidence of a beneficial effect from beta-blockers in treating anxiety symptoms in patients with social phobia or panic disorder with or without agoraphobia compared to either placebo or benzodiazepines.
A systematic review found no evidence of a beneficial effect from beta-blockers in treating anxiety symptoms in patients with social phobia or panic disorder with or without agoraphobia compared to either placebo or benzodiazepines.
A systematic review found no...
04/24/2025
Psych Congress Network
tipped over pill bottle with white pills spilling out
News
Fewer Than Half of Medicaid Managed Care Plans Cover All Medications For AUD
04/22/2025
Maria Mantas
Fewer than half of all Medicaid managed care plans (MCPs) covered all 4 US Food and Drug Administration (FDA)–approved medications for the treatment of alcohol use disorder (AUD), a cross-sectional study published in JAMA Network Open found.
Fewer than half of all Medicaid managed care plans (MCPs) covered all 4 US Food and Drug Administration (FDA)–approved medications for the treatment of alcohol use disorder (AUD), a cross-sectional study published in JAMA Network Open found.
Fewer than half of all Medicaid...
04/22/2025
Psych Congress Network
Neurons in the brain
News
Risk Factors for Late-Onset Epilepsy in Patients With Cognitive Decline Identified
04/21/2025
Jolynn Tumolo
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk...
04/21/2025
Neurology
strand of DNA
News
Genetic Liability for Schizophrenia May Affect Traumatic Brain Injury Associations
04/21/2025
Jolynn Tumolo
A genetic liability for schizophrenia and other mental disorders appears to factor into the associations between traumatic brain injury and mental disorder and suicide, according to study findings.
A genetic liability for schizophrenia and other mental disorders appears to factor into the associations between traumatic brain injury and mental disorder and suicide, according to study findings.
A genetic liability for...
04/21/2025
Psych Congress Network
injection for schizophrenia treatment
News
Antipsychotic Sedation Peaks in First 2 Weeks, Emphasizing Importance of Early Monitoring
04/21/2025
Maria Mantas
A meta-analysis of randomized controlled trials (RCTs) of antipsychotic monotherapy for the acute phase of schizophrenia and schizoaffective disorder (SSD) found that sedation onset peaked within the first 2 weeks of treatment initiation.
A meta-analysis of randomized controlled trials (RCTs) of antipsychotic monotherapy for the acute phase of schizophrenia and schizoaffective disorder (SSD) found that sedation onset peaked within the first 2 weeks of treatment initiation.
A meta-analysis of randomized...
04/21/2025
Psych Congress Network
older woman with depression
News
Evidence Lacking for TRD Treatment Effectiveness in Older Adults, Review Finds
04/16/2025
Maria Mantas
A recent systematic review found weak quality evidence to support the effectiveness of several commonly prescribed pharmacological and non-pharmacological interventions for treatment-resistant depression (TRD) in older adults. 
A recent systematic review found weak quality evidence to support the effectiveness of several commonly prescribed pharmacological and non-pharmacological interventions for treatment-resistant depression (TRD) in older adults. 
A recent systematic review found...
04/16/2025
Psych Congress Network
Viloxazine Molecule
News
Viloxazine ER: A Nonstimulant in ADHD Treatment
04/14/2025
Viloxazine ER is a nonstimulant medication for ADHD that has a unique mechanism of action compared to traditional stimulant medications, broadening the therapeutic landscape.
Viloxazine ER is a nonstimulant medication for ADHD that has a unique mechanism of action compared to traditional stimulant medications, broadening the therapeutic landscape.
Viloxazine ER is a nonstimulant...
04/14/2025
Psych Congress Network
an assortment of pills spilled out on a yellow table
News
Inpatient Addiction Consultation Service Promotes MOUD in Patients with OUD
04/14/2025
Jolynn Tumolo
According to randomized clinical trial findings, patients with opioid use disorder (OUD) who received inpatient addiction consultation service were more likely to initiate medication for OUD (MOUD) compared to those who received usual care.
According to randomized clinical trial findings, patients with opioid use disorder (OUD) who received inpatient addiction consultation service were more likely to initiate medication for OUD (MOUD) compared to those who received usual care.
According to randomized clinical...
04/14/2025
Psych Congress Network
Hormonal Contraceptive Pills
News
Post Partum Hormonal Contraception Use Linked with Heightened Depression Risk
04/09/2025
Jolynn Tumolo
The initiation of hormonal contraception post partum was associated with an immediate increase in depression risk in first-time mothers in Denmark, according to a study published in JAMA Network Open.
The initiation of hormonal contraception post partum was associated with an immediate increase in depression risk in first-time mothers in Denmark, according to a study published in JAMA Network Open.
The initiation of hormonal...
04/09/2025
Psych Congress Network
A woman taking a pill
News
New Study Finds Quetiapine More Effective Than Lithium in Reducing Treatment-Resistant Depression Symptoms
04/09/2025
Maria Mantas
Quetiapine may be more clinically effective than lithium as an augmentation option for reducing symptoms of treatment-resistant depression (TRD), a type of major depressive disorder (MDD), according to a recent study.
Quetiapine may be more clinically effective than lithium as an augmentation option for reducing symptoms of treatment-resistant depression (TRD), a type of major depressive disorder (MDD), according to a recent study.
Quetiapine may be more...
04/09/2025
Psych Congress Network

Quizzes

quiz
Quiz
Percentage of Patients With Major or Mild Frontotemporal NCD Found With Alzheimer Disease Pathology at Autopsy
07/11/2024
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients...
07/11/2024
Psych Congress Network
Why do hurricanes increase mortality risk in ADRD populations?
Quiz
Why do hurricanes increase mortality risk in ADRD populations?
04/04/2023
Do you remember this study?
Do you remember this study?
Do you remember this study?
04/04/2023
Psych Congress Network
Four pencils with their erasers spelling out "quiz."
Quiz
What strategies can individuals use to reduce their risk of Alzheimer disease?
09/28/2022
Take the quiz to test your clinical knowledge!
Take the quiz to test your clinical knowledge!
Take the quiz to test your...
09/28/2022
Psych Congress Network
Expert Insights Quiz
Expert Insights Quiz
Effective Strategies to Introduce LAIs to Patients In-Person and Via Telemedicine
04/21/2025
Craig Chepke, MD, DFAPA
Which of the following strategies did Scientific Director for the Psych Congress event portfolio, Dr Craig Chepke, highlight as effective when introducing LAIs to patients with schizophrenia, including those in telemedicine settings?
Which of the following strategies did Scientific Director for the Psych Congress event portfolio, Dr Craig Chepke, highlight as effective when introducing LAIs to patients with schizophrenia, including those in telemedicine settings?
Which of the following...
04/21/2025
Psych Congress Network
a dialogue bubble with the word "quiz"
Quiz
How do inpatient addiction consultation services impact MOUD initiation?
04/21/2025
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
04/21/2025
Psych Congress Network
stacked blocks that spell out the word "quiz"
Quiz
Initial Treatment Approach for Adults in Acute Phase MDD in Ambulatory Care
04/17/2025
Test your knowledge of initial treatment approaches for adults in the acute phase of moderate to severe MDD in ambulatory care.
Test your knowledge of initial treatment approaches for adults in the acute phase of moderate to severe MDD in ambulatory care.
Test your knowledge of initial...
04/17/2025
Psych Congress Network
a sticky note that reads "take the quiz" stuck to a computer keyboard
Quiz
How does menopausal hormone therapy impact outomes in midlife women with schizophrenia?
04/11/2025
According to a 2024 study, what impact did MHT use have on the risk of psychosis relapse in women between ages 40 and 55?
According to a 2024 study, what impact did MHT use have on the risk of psychosis relapse in women between ages 40 and 55?
According to a 2024 study, what...
04/11/2025
Psych Congress Network
an illustrated laptop screen displaying a quiz
Quiz
By What Percentage Did US Drug Overdose Deaths Decline in 2024?
04/10/2025
According to provisional data from the Center for Disease Control and Prevention (CDC), by what percentage did US drug overdose deaths decrease in the 12 months ending in September 2024 compared to the previous year?
According to provisional data from the Center for Disease Control and Prevention (CDC), by what percentage did US drug overdose deaths decrease in the 12 months ending in September 2024 compared to the previous year?
According to provisional data...
04/10/2025
Psych Congress Network
Dr Steven Chan
Expert Insights Quiz
Choosing the Right Digital Therapeutic for MDD Treatment
03/18/2025
Steven Chan, MD, MBA; Meagan Thistle
According to Psych Congress Steering Committee Member Steven Chan, MD, MBA, which of the following are important considerations when selecting and implementing digital therapeutics for the treatment of MDD?
According to Psych Congress Steering Committee Member Steven Chan, MD, MBA, which of the following are important considerations when selecting and implementing digital therapeutics for the treatment of MDD?
According to Psych Congress...
03/18/2025
Psych Congress Network
Did OUD diagnoses increase or decrease in VHA patients?
Quiz
Did OUD diagnoses increase or decrease in VHA patients?
02/25/2025
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
02/25/2025
Psych Congress Network
Charles Raison headshot
Expert Insights Quiz
First-Line Treatment Options for Insomnia
02/21/2025
Charles L. Raison, MD
True or False: According to Psych Congress Steering Committee Member, Charles Raison, MD, the first-line treatment for primary insomnia is medication, including benzodiazepines.
True or False: According to Psych Congress Steering Committee Member, Charles Raison, MD, the first-line treatment for primary insomnia is medication, including benzodiazepines.
True or False: According to...
02/21/2025
Psych Congress Network
Quiz
Quiz
Cariprazine FDA-Approved Indications
02/21/2025
Meagan Thistle
Is cariprazine FDA-approved as an adjunctive treatment for major depressive disorder (MDD)? What is another FDA-approved indication for this drug? Take the quiz to test your psychopharmacology knowledge!
Is cariprazine FDA-approved as an adjunctive treatment for major depressive disorder (MDD)? What is another FDA-approved indication for this drug? Take the quiz to test your psychopharmacology knowledge!
Is cariprazine FDA-approved as...
02/21/2025
Psych Congress Network
How many US Psychiatric Hospitals Provided Medications for OUD?
Quiz
How many US psychiatric hospitals provided medications for OUD?
02/06/2025
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
02/06/2025
Psych Congress Network

Perspectives

marc agronin md
Blog
Alzheimer Disease Prevention: Part 2
07/29/2024
Marc E. Agronin, MD
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
Leslie Citrome, MD, MPH.
Videos
Addressing Agitation in Dementia
11/09/2023
Leslie Citrome, MD
With 7 million individuals living with Alzheimer disease and dementia in the United States, effective home-based strategies are crucial to prevent institutionalization.
With 7 million individuals living with Alzheimer disease and dementia in the United States, effective home-based strategies are crucial to prevent institutionalization.
With 7 million individuals...
11/09/2023
Psychiatry & Behavioral Health
Dr Paul Schulz
Videos
Lecanemab Considerations and Efficacy
10/16/2023
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the...
10/16/2023
Psych Congress Network
Dr Paul Schulz
Videos
Patient Considerations When Prescribing Lecanemab for Alzheimer Disease
09/22/2023
Paul Schulz, MD
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the...
09/22/2023
Psych Congress Network
Dr Paul Schulz
Videos
Advantages and Drawbacks of Lecanemab in Alzheimer Disease Treatment
09/11/2023
Paul Schulz, MD
Dr Paul Shulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Shulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Shulz discusses the...
09/11/2023
Psych Congress Network
Marc Agronin, MD.
Videos
Telepsychiatry Practice for Geriatric Patients
08/11/2023
Marc E. Agronin, MD
In this exclusive video, Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, CMO, describes his experience treating geriatric patients via telehealth.
In this exclusive video, Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, CMO, describes his experience treating geriatric patients via telehealth.
In this exclusive video, Psych...
08/11/2023
Psych Congress Network
Marc Agronin, MD.
Videos
What the Data Tells Us About Telepsychiatry Efficacy and Popularity
07/20/2023
Marc E. Agronin, MD
Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, discusses the meteoric rise of telehealth in mental health care practice.
Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, discusses the meteoric rise of telehealth in mental health care practice.
Psych Congress Network Geriatric...
07/20/2023
Psych Congress Network
Marc Agronin, MD.
Blog
Alzheimer Disease Prevention
08/30/2022
Marc E. Agronin, MD
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section...
08/30/2022
Psych Congress Network
Douglas_Scharre_alzheimers_aducanumab
Videos
Putting Research Into Practice With Aducanumab for Alzheimer Disease
08/27/2021
In this video, Douglas Scharre, MD discusses his presentation “Translating Research Into Practice Everything You Need To Know About Aducanumab But Were Afraid To Ask,” which was given virtually at Neurology Week.
In this video, Douglas Scharre, MD discusses his presentation “Translating Research Into Practice Everything You Need To Know About Aducanumab But Were Afraid To Ask,” which was given virtually at Neurology Week.
In this video, Douglas Scharre,...
08/27/2021
Psych Congress Network
Headshot of Snoben Kuruvila
Videos
Emerging Rapid-Acting Intervention Options for the Treatment of MDD
04/24/2025
Following his insightful session at Psych Congress 2024, Snoben Kuruvila, MPAS, PA-C, sat down with Psych Congress Network to discuss emerging developments in major depressive disorder (MDD) treatment.
Following his insightful session at Psych Congress 2024, Snoben Kuruvila, MPAS, PA-C, sat down with Psych Congress Network to discuss emerging developments in major depressive disorder (MDD) treatment.
Following his insightful session...
04/24/2025
Psych Congress Network
headshot of Dr Craig Chepke
Videos
Effective Communication Strategies for Introducing LAIs in Telemedicine Settings
04/16/2025
Craig Chepke, MD, DFAPA
In this video, Craig Chepke, MD, DFAPA, discusses effective communication strategies clinicians can use when introducing long-acting injectable (LAI) antipsychotics to patients for the treatment of schizophrenia.
In this video, Craig Chepke, MD, DFAPA, discusses effective communication strategies clinicians can use when introducing long-acting injectable (LAI) antipsychotics to patients for the treatment of schizophrenia.
In this video, Craig Chepke, MD,...
04/16/2025
Psych Congress Network
headshot of Dr Mohamed Abdelwahab
Q&As
OSA Treatment Outcomes Highlight Impact of Interdisciplinary Care
04/15/2025
Mohamed Abdelwahab, MD, PhD
Mohamed A. Abdelwahab, MD, PhD, discusses his recent meta-analysis comparing the mental health impacts of CPAP and surgical interventions.
Mohamed A. Abdelwahab, MD, PhD, discusses his recent meta-analysis comparing the mental health impacts of CPAP and surgical interventions.
Mohamed A. Abdelwahab, MD, PhD,...
04/15/2025
Psych Congress Network
headshot of Dr Julie Carbray
Q&As
How Clinicians Can Navigate Stimulant vs Nonstimulant Treatments for ADHD
04/11/2025
Julie A. Carbray, PhD, APRN
2025 Psych Congress NP Institute Co-Chair Julie Carbray, PhD, PMHNP-BC, PMHCNS-BC, APRN, shares how clinicians can best navigate between stimulant and nonstimulant treatment options for patients with ADHD.
2025 Psych Congress NP Institute Co-Chair Julie Carbray, PhD, PMHNP-BC, PMHCNS-BC, APRN, shares how clinicians can best navigate between stimulant and nonstimulant treatment options for patients with ADHD.
2025 Psych Congress NP Institute...
04/11/2025
Psych Congress NP Institute
Kristian Dambrino, MSN
Videos
When Monotherapy Doesn’t Work: Treatment Resistance in Tardive Dyskinesia
04/08/2025
Kristian Dambrino, MSN, APRN, PMHNP
Psych Congress Faculty Member Kristian Dambrino, DNP, PMHNP-BC, dives into the nuances of prescribing vesicular monoamine transporter 2 (VMAT-2) inhibitors for the long-term management of TD.
Psych Congress Faculty Member Kristian Dambrino, DNP, PMHNP-BC, dives into the nuances of prescribing vesicular monoamine transporter 2 (VMAT-2) inhibitors for the long-term management of TD.
Psych Congress Faculty Member...
04/08/2025
Psych Congress Network
Thomas L. Schwartz, MD
Q&As
A Psychiatrist’s Role in Tackling Sleep-Wake Disorders
03/18/2025
Thomas L. Schwartz, MD, explores medicine’s evolving understanding of insomnia, narcolepsy, and idiopathic hypersomnia from a neuroscientific perspective.
Thomas L. Schwartz, MD, explores medicine’s evolving understanding of insomnia, narcolepsy, and idiopathic hypersomnia from a neuroscientific perspective.
Thomas L. Schwartz, MD, explores...
03/18/2025
Psych Congress Network
Brittany Albright
Q&As
Evaluating Anhedonia With Patient-Centered Strategies
03/11/2025
In part 2 of this Q and A, Brittany Albright, MD, MPH, Psych Congress Elevate faculty member and founder of Sweetgrass Psychiatry, discusses 2 of her favorite anhedonia treatment strategies.
In part 2 of this Q and A, Brittany Albright, MD, MPH, Psych Congress Elevate faculty member and founder of Sweetgrass Psychiatry, discusses 2 of her favorite anhedonia treatment strategies.
In part 2 of this Q and...
03/11/2025
Psych Congress Network
Dr Brittany Albright
Q&As
Exploring Anhedonia in Psychiatric Care
03/04/2025
In this Q&A, Psych Congress Elevate faculty member Dr Brittany Albright discusses the challenging symptoms of anhedonia and its significant impact on patients' quality of life and clinical outcomes.
In this Q&A, Psych Congress Elevate faculty member Dr Brittany Albright discusses the challenging symptoms of anhedonia and its significant impact on patients' quality of life and clinical outcomes.
In this Q&A, Psych Congress...
03/04/2025
Psych Congress Network
Examining Novel Treatment Methods in Schizophrenia
Videos
Examining Novel Treatment Methods in Schizophrenia
02/25/2025
Christoph U. Correll, MD
In this discussion, Christoph Correll, MD, professor of psychiatry at the Zucker School of Medicine, delves into the groundbreaking FDA approval of xanomeline/tropsium chloride, a novel treatment for schizophrenia that moves beyond...
In this discussion, Christoph Correll, MD, professor of psychiatry at the Zucker School of Medicine, delves into the groundbreaking FDA approval of xanomeline/tropsium chloride, a novel treatment for schizophrenia that moves beyond...
In this discussion, Christoph...
02/25/2025
Psych Congress Network
Steven Chan, MD, MBA, FAPA, FAMIA
Videos
Barriers and Misconceptions to Digital Therapeutic Integration
02/14/2025
Steven Chan, MD, MBA
In this video, Steven Chan, MD, MBA, FAPA, FAMIA, Psych Congress Steering Committee, explains some of the barriers that virtual clinicians should anticipate when weighing digital therapeutic options for major depressive disorder (MDD)...
In this video, Steven Chan, MD, MBA, FAPA, FAMIA, Psych Congress Steering Committee, explains some of the barriers that virtual clinicians should anticipate when weighing digital therapeutic options for major depressive disorder (MDD)...
In this video, Steven Chan, MD,...
02/14/2025
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Sign Up

Psych Congress Network Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use